专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004037209A3 METHODS TO PREVENT TUMOR RECURRENCE BY BLOCKADE OF TGF-beta 审中-公开
标题翻译：通过阻断TGF-β预防肿瘤复发的方法
公开(公告)号：WO2004037209A3
公开(公告)日：2004-11-25
申请号：PCT/US0334023
申请日：2003-10-24
申请人： US GOV HEALTH & HUMAN SERV , BERZOFSKY JAY A , TERABE MASAKI , MATSUI SO
发明人： BERZOFSKY JAY A , TERABE MASAKI , MATSUI SO
IPC分类号： A61K38/00 , C07K16/22 , A61K39/395
CPC分类号： G01N33/74 , A61K2039/505 , C07K16/22 , C07K2317/76 , G01N33/5011 , G01N33/5041 , G01N33/5047 , G01N2333/495
摘要： Methods are provided herein to prevent a tumor recurrence in a subject, involving administering to the subject an agent that blocks the TGF-beta signaling pathway. In one embodiment, the agent inhibits the immunosuppressive effects of TGF-beta. Also provided is a method of enhancing an immune respond in a subject to inhibit recurrence of a tumor by administering an agent which blocks the TGF-beta signaling pathway. A method of enhancing the activity of an immune cell to inhibit recurrence of a tumor by contacting a TGF-beta receptor-expressing cell with an agent which blocks the TGF-beta signaling pathway is also provided, as are methods of screening for an agent that inhibits or measurably reduces the recurrence of a tumor.
摘要翻译：本文提供了用于预防受试者肿瘤复发的方法，涉及给受试者施用阻断TGF-β信号传导途径的药剂。在一个实施方案中，所述药剂抑制TGF-β的免疫抑制作用。还提供了通过施用阻断TGF-β信号传导途径的试剂来增强受试者中的免疫应答以抑制肿瘤复发的方法。还提供了通过使TGF-β受体表达细胞与阻断TGF-β信号传导途径的试剂接触来增强免疫细胞活性以抑制肿瘤复发的方法，如筛选抑制或可测量地减少肿瘤的复发。

2. 发明申请

WO02055100A2 METHOD AND COMPOSITION FOR ENHANCING AN IMMUNE RESPONSE 审中-公开
标题翻译：增强免疫反应的方法和组合
公开(公告)号：WO02055100A2
公开(公告)日：2002-07-18
申请号：PCT/US0151339
申请日：2001-10-22
申请人： INST GENETICS LLC , US GOV HEALTH & HUMAN SERV , BERZOFSKY JAY A , TERABE MASAKI , DONALDSON DEBRA D , MATSUI SO , NOBEN-TRAUTH NANCY , PAUL WILLIAM E
发明人： BERZOFSKY JAY A , TERABE MASAKI , DONALDSON DEBRA D , MATSUI SO , NOBEN-TRAUTH NANCY , PAUL WILLIAM E
IPC分类号： A61K47/34 , A61K38/00 , A61K38/17 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/00 , A61K48/00 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P37/04 , C07K14/54 , C07K16/24 , C07K16/28
CPC分类号： C07K16/244 , A61K38/1793 , A61K38/208 , A61K39/39 , A61K2039/505 , A61K2039/55516 , A61K2039/55538 , C07K16/2812 , C07K2319/30 , A61K2300/00
摘要： Provided is a method and composition for enhancing an immune response in a subject by administering to the subject an inhibitor of IL-13 or an inhibitor of an NK-T cell to the subject. The method can be used to prevent growth of a tumor in the subject, e.g., to inhibit tumor recurrence or metastasis. The method can also be used to enhance a response to a vaccine in a subject.
摘要翻译：本发明提供了一种通过向受试者施用IL-13抑制剂或NK-T细胞抑制剂来对受试者增强受试者的免疫应答的方法和组合物。该方法可用于预防受试者中肿瘤的生长，例如抑制肿瘤复发或转移。该方法还可用于增强对受试者中疫苗的反应。

3. 发明申请

WO02055100A9 Method and composition for inhibition of tumor growth and enhancing an immune response 审中-公开
标题翻译：用于抑制肿瘤生长和增强免疫应答的方法和组合物
公开(公告)号：WO02055100A9
公开(公告)日：2006-05-11
申请号：PCT/US0151339
申请日：2001-10-22
申请人： BERZOFSKY JAY A , TERABE MASAKI , DONALDSON DEBRA D , MATSUI SO , NOBEN-TRAUTH NANCY , PAUL WILLIAM E , INST GENETICS LLC , US GOV HEALTH & HUMAN SERV
发明人： BERZOFSKY JAY A , TERABE MASAKI , DONALDSON DEBRA D , MATSUI SO , NOBEN-TRAUTH NANCY , PAUL WILLIAM E
IPC分类号： A61K47/34 , A61K38/00 , A61K38/17 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/00 , A61K48/00 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P37/04 , C07K14/54 , C07K16/24 , C07K16/28
CPC分类号： C07K16/244 , A61K38/1793 , A61K38/208 , A61K39/39 , A61K2039/505 , A61K2039/55516 , A61K2039/55538 , C07K16/2812 , C07K2319/30 , A61K2300/00
摘要： Provided is a method and composition for enhancing an immune response in a subject by administering to the subject an inhibitor of IL-13 or an inhibitor of an NK-T cell to the subject. The method can be used to prevent growth of a tumor in the subject, e.g., to inhibit tumor recurrence or metastasis. The method can also be used to enhance a response to a vaccine in a subject.
摘要翻译：本发明提供了一种通过向受试者施用IL-13抑制剂或NK-T细胞抑制剂来增强受试者的免疫应答的方法和组合物。该方法可用于预防受试者中肿瘤的生长，例如抑制肿瘤复发或转移。该方法还可用于增强对受试者中疫苗的反应。

4. 发明申请

WO2009018429A2 TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-a2 审中-公开
标题翻译：通过IL-13受体-a2的靶向治疗癌症
公开(公告)号：WO2009018429A2
公开(公告)日：2009-02-05
申请号：PCT/US2008071736
申请日：2008-07-31
申请人： US GOV HEALTH & HUMAN SERV , STROBER WARREN , BERZOFSKY JAY A , FICHTNER-FEIGL STEFAN , KITANI ATSUSHI , FUSS IVAN J , TERABE MASAKI , MANNON PETER
发明人： STROBER WARREN , BERZOFSKY JAY A , FICHTNER-FEIGL STEFAN , KITANI ATSUSHI , FUSS IVAN J , TERABE MASAKI , MANNON PETER
IPC分类号： A61K39/395 , A61K38/17 , A61P35/00
CPC分类号： A61K31/00 , A61K38/1793 , A61K2039/505 , C07K16/241 , C12N15/1138 , C12N2310/13 , C12N2310/14
摘要： Disclsoed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL- 13Ra2 antagonist, and/or a AP-I antagonist.
摘要翻译：本文中所述的是用于治疗或预防涉及使用TNF-α拮抗剂，IL-13Ra2拮抗剂和/或AP-1拮抗剂的癌症的组合物和方法。

5. 发明申请

WO2005058944A3 IMMUNOGENIC PEPTIDES FRAGMENTS OF XAGE-1 审中-公开
标题翻译： XAGE-1免疫原性片段
公开(公告)号：WO2005058944A3
公开(公告)日：2006-01-05
申请号：PCT/US2004041639
申请日：2004-12-13
申请人： US GOV HEALTH & HUMAN SERV , BERZOFSKY JAY A , PASTAN IRA H , TERABE MASAKI
发明人： BERZOFSKY JAY A , PASTAN IRA H , TERABE MASAKI
IPC分类号： C07K14/47 , A61K38/17 , A61P35/00
CPC分类号： C07K7/06 , A61K39/0011 , A61K45/06 , C07K14/4748
摘要： XAGE-1 is a gene expressed in a number of important human cancers, including prostate cancer, lung cancer, breast cancer, ovarian cancer, glioblastoma, pancreatic cancer, and melanoma. It has now been discovered that peptides of fifty or fewer amino acids comprising the sequence X 1 X 2 X 3 PSAPSPX 4 (SEQ ID NO:5), where X 1 is any amino acid and is preferably G or Y; X 2 is selected from the group consisting of L, M, A, I, V, and T, with L and M being preferred; X 3 is a hydrophobic residue, M or A; and X 4 is V, M, L, A, I, or T, and is preferably V, bind to the HLA-A2 MHC class I molecule, and can be used to raise immune responses to XAGE-1-expressing cancers. In some embodiments, the P at position 7, the S at position 8, or the P at position 9, can be omitted to create a 9 amino acid peptide. The invention provides immunogenic peptides, nucleic acids encoding them, vectors comprising the nucleic acids, uses of the peptides and nucleic acids for manufacture of medicaments, methods of using the peptides and nucleic acids, and compositions of the peptides or nucleic acids in pharmaceutically acceptable carriers.
摘要翻译： XAGE-1是在许多重要的人类癌症中表达的基因，包括前列腺癌，肺癌，乳腺癌，卵巢癌，胶质母细胞瘤，胰腺癌和黑素瘤。现在已经发现，包含序列X 1，X 2，X 3，CPSPSPX 4的五十个或更少的氨基酸的肽， SUB（SEQ ID NO：5），其中X 1是任何氨基酸，优选为G或Y; X 2选自L，M，A，I，V和T，其中L和M是优选的; X 3是疏水残基M或A; 并且X 4是V，M，L，A，I或T，并且优选为V，结合HLA-A2 MHC I类分子，并且可用于提高对XAGE的免疫应答 -1表达的癌症。在一些实施方案中，可以省略位置7处的P，位置8处的S或位置9处的P，以产生9个氨基酸的肽。本发明提供免疫原性肽，编码它们的核酸，包含核酸的载体，肽和核酸用于制备药物的用途，使用肽和核酸的方法，以及肽或核酸在药学上可接受的载体中的组合物。

6. 发明申请

WO2006089251A3 SYNERGISTIC EFFECT OF TGF-ß BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS 审中-公开
标题翻译： TGF-β片段和免疫原性对肿瘤的协同作用
公开(公告)号：WO2006089251A3
公开(公告)日：2006-12-28
申请号：PCT/US2006005888
申请日：2006-02-16
申请人： US GOV HEALTH & HUMAN SERV , TERABE MASAKI , TAKAKU SHUN , BERZOFSKY JAY A
发明人： TERABE MASAKI , TAKAKU SHUN , BERZOFSKY JAY A
IPC分类号： A61K39/395 , A61K39/00 , A61K39/12 , A61K41/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/04 , C07K14/025 , C07K16/22
CPC分类号： A61K39/39 , A61K39/0011 , A61K39/12 , A61K39/3955 , A61K39/39558 , A61K2039/5152 , A61K2039/55516 , A61K2039/55522 , A61K2039/55566 , A61K2039/585 , C07K16/22 , C12N2710/20022 , C12N2710/20034 , A61K2300/00
摘要： Methods are provided herein for synergistically affecting tumor growth in a subject, involving the administration to the subject of an agent that blocks the TGF- ß signaling pathway in combination with an immunogenic agent. The agent that blocks the TGF-ß signaling pathway is believed to inhibit the immunosuppressive effects of TGF-ß, while the immunogenic agent is believed to enhance an immune response. Surprisingly, the combination of such elements produces a synergistic effect. In one embodiment, the administration of the IDl 1.16 anti-TGF-ß antibody in combination with the human papilloma virus E7(49-57) peptide enhances tumor regression and tumor-specific CTL response in the subject. In another embodiment, the administration of the IDl 1.16 anti-TGF-ß antibody in combination with irradiated CT26 cells enhances tumor regression in the subject. The method of administering the combination of agents to the subject is more effective than the administration of each agent individually, or the sum of their individual effects.
摘要翻译：本文提供了协同地影响受试者的肿瘤生长的方法，涉及向受试者施用阻断TGF-β信号通路的试剂与免疫原性试剂的组合。认为阻断TGF-β信号通路的药物可以抑制TGF-β的免疫抑制作用，而免疫原性药物被认为可增强免疫反应。令人惊讶的是，这些元素的组合产生协同效应。在一个实施方案中，ID11.16抗TGF-β抗体与人乳头状瘤病毒E7（49-57）组合的施用增强受试者的肿瘤消退和肿瘤特异性CTL应答。在另一个实施方案中，ID11.16抗TGF-β抗体与照射的CT26细胞的组合的施用增强了受试者的肿瘤消退。给予受试者的药物组合的方法比单独施用每种药剂或其各自作用的总和更有效。

7. 发明申请

WO2011112889A3 β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY 审中-公开
标题翻译： β-MANNOSYLCERAMIDE和NKT细胞抗肿瘤免疫刺激
公开(公告)号：WO2011112889A3
公开(公告)日：2015-09-03
申请号：PCT/US2011028024
申请日：2011-03-11
申请人： US HEALTH , UNIV BIRMINGHAM OF EDGBASTON , BERZOFSKY JAY A , O'KONEK JESSICA , TERABE MASAKI , ILLARIONOV PETR A , BESRA GURDYAL S
发明人： BERZOFSKY JAY A , O'KONEK JESSICA , TERABE MASAKI , ILLARIONOV PETR A , BESRA GURDYAL S
IPC分类号： A61K9/08 , A61K9/00 , A61K9/10 , A61K9/14 , A61K31/7004 , A61P35/00
CPC分类号： A61K31/7032 , A61K31/7004 , A61K38/2013 , A61K39/00 , A61K39/0011 , A61K45/06 , A61K2039/585 , C07H15/04 , C07H15/06
摘要： β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.
摘要翻译： β-甘露糖基神经酰胺或其盐或溶剂合物在药学上可接受的载体中，用作I型NKT细胞激动剂与治疗有效量的α-半乳糖神经酰胺或其盐或溶剂合物，和/或至少一种或多种 T细胞共刺激分子，公开。还提供了包含β-甘露糖基神经酰胺的组合物以及治疗肿瘤的方法。

8. 发明申请

WO2011112599A3 IMMUNOGENIC POTE PEPTIDES AND METHODS OF USE 审中-公开
标题翻译：免疫原性多肽和使用方法
公开(公告)号：WO2011112599A3
公开(公告)日：2011-11-10
申请号：PCT/US2011027577
申请日：2011-03-08
申请人： US HEALTH , BERZOFSKY JAY A , HUANG YI-HSIANG , TERABE MASAKI , PASTAN IRA H
发明人： BERZOFSKY JAY A , HUANG YI-HSIANG , TERABE MASAKI , PASTAN IRA H
IPC分类号： A61K39/00 , A61P35/00
CPC分类号： C07K14/4748 , A61K39/0011 , A61K48/00 , A61K2039/55516 , A61K2039/55522 , A61K2039/55538 , A61K2039/57 , C12N2730/10111
摘要： POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.
摘要翻译：最近POTE被鉴定为在各种人类癌症中表达的肿瘤抗原，包括结肠癌，卵巢癌，乳腺癌，前列腺癌，肺癌和胰腺癌。本文描述了结合MHC I类分子的免疫原性POTE多肽，包括修饰的POTE多肽。免疫原性POTE多肽能够诱导针对表达POTE的肿瘤细胞的免疫应答。因此，本文提供了在受试者（例如具有表达POTE的癌症的类型的受试者）中引发免疫应答的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式